Drug Patents owned by Genzyme Corp

1. Drug name - CAPRELSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42353 GENZYME CORP Quinazoline derivatives and pharmaceutical compositions containing them
Jun, 2022

(3 months ago)

CN1231662A GENZYME CORP Quinazoline Derivatives And Pharmaceutical Composition Containing Quinazoline Derivative
Sep, 2017

(5 years ago)

CN1142920C GENZYME CORP Quinazoline Derivatives And Pharmaceutical Composition Thereof And Preparation Method And Application Thereof
Sep, 2017

(5 years ago)

EP929530B1 GENZYME CORP Quinazoline Derivatives And Pharmaceutical Compositions Containing Them
Sep, 2017

(5 years ago)

EP929530A1 GENZYME CORP Quinazoline Derivatives And Pharmaceutical Compositions Containing Them
Sep, 2017

(5 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474 Aug, 2028

(5 years from now)

Drugs and Companies using VANDETANIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

2. Drug name - CERDELGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916802 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(5 months ago)

US7196205 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Jun, 2026

(3 years from now)

EP2266968A3 GENZYME CORP Synthesis Of Udp-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors
Jul, 2022

(2 months ago)

EP2266968A2 GENZYME CORP Synthesis Of Udp-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors
Jul, 2022

(2 months ago)

EP2266968B1 GENZYME CORP Synthesis Of Udp-Glucose: N-Acylsphingosine Glucosyltransferase Inhibitors
Jul, 2022

(2 months ago)

EP2067775A1 GENZYME CORP A N-Acylsphingosine Glucosyltransferase Inhibitor
Jul, 2022

(2 months ago)

EP2067775B1 GENZYME CORP A N-Acylsphingosine Glucosyltransferase Inhibitor
Jul, 2022

(2 months ago)

EP1409467B1 GENZYME CORP A N-Acylsphingosine Glucosyltransferase Inhibitor
Jul, 2027

(4 years from now)

EP1409467A1 GENZYME CORP A N-Acylsphingosine Glucosyltransferase Inhibitor
Jul, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase Jan, 2031

(8 years from now)

US10888544 GENZYME CORP Methods for treating Gaucher disease Dec, 2038

(16 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with mild hepatic impairment and are concurrently taking a strong or moderate cyp3a inhibitor

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 84MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.